<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="382">
  <stage>Registered</stage>
  <submitdate>3/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <actrnumber>ACTRN12605000370606</actrnumber>
  <trial_identification>
    <studytitle>A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate the Photoprotective Effect of a Sustained Release dose of Melanotan in Fair skinned Healthy Caucasians</studytitle>
    <scientifictitle>A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate the Photoprotective Effect of a Sustained Release dose of Melanotan in Fair skinned Healthy Caucasians</scientifictitle>
    <utrn />
    <trialacronym>EP008</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Sunburn</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Normal skin development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>EPT 1647 - 3 months</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare erythemal response 24hr post solar-stimulated irradiation in Melanotan-treated and placebo-treated individuals</outcome>
      <timepoint>At 4, 8 and 12 weeks after initiation of dosing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the incidence of DNA damage (thymine dimers) elicited 30 minutes after controlled solar irradiation (3x MED) to a small area of buttock skin (1 x 1 cm).</outcome>
      <timepoint>At baseline and 8 weeks after initiation of dosing with Melanotan or placebo.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy Caucasian men and women.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>History of skin cancer.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed code break envelopes</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Computer software SAS was used for the random allocation sequence and the blocking restriction method was used.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>4/06/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>48</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Epitan Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Epitan Limited</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr V Pua</name>
      <address>Royal Prince Alfred Hospital
Missenden Road
Camperdown
NSW 2050</address>
      <phone>02 9515 6111</phone>
      <fax />
      <email>vernonpua@yahoo.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof R Barnetson</name>
      <address>Royal Prince Alfred Hospital
Missenden Road
Camperdown
NSW 2050</address>
      <phone>02 9515 6111</phone>
      <fax />
      <email>ross.barnetson@email.cs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>